2024年10月23日,和誉医药(港交所代码:02256)宣布,公司两项临床前研究结果在10月于西班牙巴塞罗那举行的第36届国际分子靶标与癌症治疗大会上发布(EORTC-NCI-AACR conference, 以下简称ENA大会)。这两项研究成果分别展示了和誉医药在研管线中潜在同类最优的PRMT5*MTA抑制剂和口服KRASG12D小分子抑制剂的最新临床前研...
2024年10月23日,和誉医药(港交所代码:02256)宣布,公司两项临床前研究结果在10月于西班牙巴塞罗那举行的第36届国际分子靶标与癌症治疗大会上发布(EORTC-NCI-AACR conference, 以下简称ENA大会)。这两项研究成果分别展示了和誉医药在研管线中潜在同类最优的PRMT5*MTA抑制剂和口服KRASG12D小分子抑制剂的最新临床前研...
2023年10月16日,和誉医药(港交所代码:02256)宣布,公司两项临床前研究结果在10月于美国波士顿举行的第35届国际分子靶标与癌症治疗大会上发布(EORTC-NCI-AACR conference, 以下简称ENA大会)。这两项研究成果分别展示了和誉医药在研管线中新一代PRMT5*MTA抑制剂和可入脑PD-L1小分子抑制剂的最新临床前研究进展。作...
2023年10月16日,和誉医药(港交所代码:02256)宣布,公司两项临床前研究结果在10月于美国波士顿举行的第35届国际分子靶标与癌症治疗大会上发布(EORTC-NCI-AACR conference, 以下简称ENA大会)。这两项研究成果分别展示了和誉医药在研管线中新一代PRMT5*MTA抑制剂和可入脑PD-L1小分子抑制剂的最新临床前研究进展。作...
home / conference / eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics Content TypeCasdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma By Kristi Rosa November 2nd 2024 Casdatifan was well tolerated and had durable clinical activity in patients with...
AACR-NCI- EORTC International Conference on Molecular Targets, Cancer Ther- apeutics, Miami Beach.Erba E, Bassano L, Di Liberti G, Muradore I, Codegoni AM, Celli N and D'Incalci M. (1999). Proc. AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics, (...
This article presents and discusses the most clinically relevant reports presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Miami, Florida, with a focus on angiogenesis inhibitors and signal transduction inhibitors. This conference, which ...
Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and...
(Nov. 2011). " Mechanism of Action of Iniparib: Stimulation of Reactive Oxygen Species (ROS) Production in an Iniparib-Sensitive Breast Cancer Cell Line, " American Association for Cancer Research, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held on Nov. 12...
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics September 18, 2023 CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: ...